Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept
Vox Sanguinis · 2023
DOI: 10.1111/vox.13545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Felix Camirand Lemyre und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculté des sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: COVID-19 Immunity Task Force (CITF), Public Health Agency of Canada (PHAC).
Abstract (Originalsprache)
Background and Objectives In this proof‐of‐concept study, which included blood donor samples, we aimed to demonstrate how Bayesian latent class models (BLCMs) could be used to estimate SARS‐CoV‐2 seroprevalence in the absence of a gold standard assay under a two‐phase sampling design. Materials and Methods To this end, 6810 plasma samples from blood donors who resided in Québec (Canada) were collected from May to July 2020 and tested for anti‐SARS‐CoV‐2 antibodies using seven serological assays (five commercial and two non‐commercial).
Results
SARS‐CoV‐2 seroprevalence was estimated at 0.71% (95% credible interval [CrI] = 0.53%–0.92%). The cPass assay had the lowest sensitivity estimate (88.7%; 95% CrI = 80.6%–94.7%), while the Héma‐Québec assay had the highest (98.7%; 95% CrI = 97.0%–99.6%).
Conclusion
The estimated low seroprevalence (which indicates a relatively limited spread of SARS‐CoV‐2 in Quebec) might change rapidly—and this tool, developed using blood donors, could enable a rapid update of the prevalence estimate in the absence of a gold standard. Further, the present analysis illustrates how a two‐stage BLCM sampling design, along with blood donor samples, can be used to estimate the performance of new diagnostic tests and inform public health decisions regarding a new or emerging disease for which a perfect reference standard does not exist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculté des sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
- Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
- Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
- McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada.
- Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montreal - McGill University Health Centre, Montreal, Quebec, Canada.
- Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Felix Camirand Lemyre, Karen Colwill, Anne-Claude Gingras, Meghan McLennan, Antoine Lewin
Förderung
- COVID-19 Immunity Task Force (CITF)
- Public Health Agency of Canada (PHAC)
Zitieren
APA
Camirand Lemyre, F., Honfo, S. H., Caya, C., Cheng, M. P., Colwill, K., Corsini, R., Gingras, A. C., Jassem, A., Krajden, M., Márquez, A. C., Mazer, B. D., McLennan, M., Renaud, C., Yansouni, C. P., Papenburg, J., & Lewin, A. (2023). Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept. Vox Sanguinis. https://doi.org/10.1111/vox.13545
Vancouver
Camirand Lemyre F, Honfo SH, Caya C, Cheng MP, Colwill K, Corsini R, et al. Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept. Vox Sanguinis. 2023. doi:10.1111/vox.13545
BibTeX
@article{CamirandLemyre2023,
author = {Camirand Lemyre, Felix and Honfo, Sewanou Hermann and Caya, Chelsea and Cheng, Matthew P and Colwill, Karen and Corsini, Rachel and Gingras, Anne-Claude and Jassem, Agatha and Krajden, Mel and Márquez, Ana Citlali and Mazer, Bruce D and McLennan, Meghan and Renaud, Christian and Yansouni, Cedric P and Papenburg, Jesse and Lewin, Antoine},
title = {Two‐phase Bayesian latent class analysis to assess diagnostic test performance in the absence of a gold standard: COVID ‐19 serological assays as a proof of concept},
journal = {Vox Sanguinis},
year = {2023},
doi = {10.1111/vox.13545}
}
EUVIMED